AMSTERDAM–(BUSINESS WIRE)–Tornier (NASDAQ: TRNX), a global leader in extremity orthopaedics, today announced the launch of its BioFiber® Surgical Mesh for the repair of rotator cuff and other tendon and ligament injuries at the 30th Annual Meeting of the Arthroscopic Association of North America (AANA) held in San Francisco. Utilized to treat over 100 patients since its limited commercial release in December 2010, the BioFiber Surgical Mesh complements Tornier’s expanding line of biologic products for upper and lower extremity surgeons, including the Conexa™ Reconstructive Tissue Matrix that has been in clinical use since 2008.
John W. Sperling, MD, MBA, Professor of Orthopedic Surgery at the Mayo Clinic in Rochester, Minnesota, commented, “Surgery for the re-attachment of tendons or ligaments to bone, such as a rotator cuff repair, can be associated with a later re-tear at the attachment site, especially in patients with compromised healing function. BioFiber’s unique mesh design and its biocompatible resorbable polymer composition provide an ideal scaffold to support healing at these surgical attachment sites. Combined with its ease of use and cost effectiveness, I have found the BioFiber Surgical Mesh to be a useful product in my practice to reinforce attachment sites during tendon and ligament surgeries.”
Under development by Tornier for over three years, BioFiber Surgical Mesh is distinguished by both its mesh design and polymer composition. The mesh is a proprietary three dimensional structure designed to provide a strong, but flexible scaffold for cell migration and enhanced healing. The fibers of the mesh are derived from a new class of proprietary resorbable polymers called polyhydroxyalkanoates (PHAs). Developed by Tornier’s corporate partner, Tepha Medical Devices of Lexington, Massachusetts, the PHA family of resorbable polymers is characterized by a unique profile of strength, flexibility, and tissue compatibility that is ideal for a broad range of implantable medical devices.
Tornier N.V. is a global medical device company focused on serving extremities specialists who treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot. The Company’s broad offering of over 80 product lines includes joint replacement, trauma, sports medicine, and biologic products to treat the extremities, as well as joint replacement products for the hip and knee in certain international markets. Since its founding approximately 70 years ago, Tornier’s “Specialists Serving Specialists” philosophy has fostered a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology stemming from its close collaboration with orthopaedic surgeons and thought leaders throughout the world. For more information regarding Tornier, visit www.tornier.com.
Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future events and often can be identified by words such as “expect,” “anticipate,” “intend,” “will,” “may,” “believe,” “could,” “continue,” “estimate,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Tornier’s actual results to be materially different than those expressed in or implied by Tornier’s forward-looking statements. For Tornier, such uncertainties and risks include, among others, the timing of regulatory approvals and introduction of new products, physician acceptance, endorsement, and use of new products; the effect of regulatory actions, changes in and adoption of reimbursement rates, potential product recalls and competitor activities. More detailed information on these and other factors that could affect Tornier’s actual results are described in Tornier’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K. Tornier undertakes no obligation to update its forward-looking statements.